CN117083282A - 可用作hiv整合酶抑制剂的四环杂环化合物 - Google Patents

可用作hiv整合酶抑制剂的四环杂环化合物 Download PDF

Info

Publication number
CN117083282A
CN117083282A CN202280022034.3A CN202280022034A CN117083282A CN 117083282 A CN117083282 A CN 117083282A CN 202280022034 A CN202280022034 A CN 202280022034A CN 117083282 A CN117083282 A CN 117083282A
Authority
CN
China
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
hiv
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280022034.3A
Other languages
English (en)
Chinese (zh)
Inventor
T·J·浩亭
J·A·麦考利
于涛
张永连
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme BV
Original Assignee
Merck Sharp and Dohme BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme BV filed Critical Merck Sharp and Dohme BV
Publication of CN117083282A publication Critical patent/CN117083282A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN202280022034.3A 2021-02-16 2022-02-14 可用作hiv整合酶抑制剂的四环杂环化合物 Pending CN117083282A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163149927P 2021-02-16 2021-02-16
US63/149927 2021-02-16
PCT/US2022/016261 WO2022177840A1 (en) 2021-02-16 2022-02-14 Tetracyclic heterocycle compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
CN117083282A true CN117083282A (zh) 2023-11-17

Family

ID=80625127

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280022034.3A Pending CN117083282A (zh) 2021-02-16 2022-02-14 可用作hiv整合酶抑制剂的四环杂环化合物

Country Status (11)

Country Link
US (1) US11958864B2 (https=)
EP (1) EP4294813B1 (https=)
JP (1) JP2024507788A (https=)
KR (1) KR20230147131A (https=)
CN (1) CN117083282A (https=)
AR (1) AR124868A1 (https=)
CA (1) CA3208396A1 (https=)
ES (1) ES3048138T3 (https=)
MX (1) MX2023009445A (https=)
TW (1) TW202246286A (https=)
WO (1) WO2022177840A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
PE20221569A1 (es) 2020-02-24 2022-10-06 Gilead Sciences Inc Compuestos tetraciclicos para el tratamiento de infecciones por vih
ES3064867T3 (en) 2020-09-30 2026-04-29 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds for a use in the treatment of hiv
US11613546B2 (en) 2021-01-19 2023-03-28 Gilead Sciences, Inc. Substituted pyridotriazine compounds and uses thereof
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
EP4704976A1 (en) * 2023-04-28 2026-03-11 Merck Sharp & Dohme LLC Delivery devices for anti-hiv compounds

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473494A (zh) * 2015-12-31 2018-08-31 默沙东公司 作为hiv整合酶抑制剂的稠合三环杂环化合物
CN110214142A (zh) * 2016-12-02 2019-09-06 默沙东公司 可用作hiv整合酶抑制剂的四环杂环化合物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010011814A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5551697B2 (ja) * 2008-07-25 2014-07-16 ビーブ・ヘルスケア・カンパニー 化合物
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
DK2620436T3 (en) * 2010-09-24 2018-07-30 Shionogi & Co Substituted polycyclic carbamoylpyridone derivative prodrug
EP3573984A4 (en) * 2017-01-26 2020-07-29 Merck Sharp & Dohme Corp. USEFUL SUBSTITUTE QUINOLIZINE DERIVATIVES AS HIV INTEGRASE INHIBITORS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108473494A (zh) * 2015-12-31 2018-08-31 默沙东公司 作为hiv整合酶抑制剂的稠合三环杂环化合物
CN110214142A (zh) * 2016-12-02 2019-09-06 默沙东公司 可用作hiv整合酶抑制剂的四环杂环化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
魏敏杰: "《药物代谢动力学》", 31 October 2011, 上海科学技术出版社, pages: 275 - 276 *

Also Published As

Publication number Publication date
AU2022223241A1 (en) 2023-08-24
EP4294813A1 (en) 2023-12-27
AR124868A1 (es) 2023-05-10
US20220259227A1 (en) 2022-08-18
KR20230147131A (ko) 2023-10-20
MX2023009445A (es) 2023-08-25
US11958864B2 (en) 2024-04-16
TW202246286A (zh) 2022-12-01
WO2022177840A1 (en) 2022-08-25
JP2024507788A (ja) 2024-02-21
ES3048138T3 (en) 2025-12-09
EP4294813B1 (en) 2025-09-10
CA3208396A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
CN117083282A (zh) 可用作hiv整合酶抑制剂的四环杂环化合物
JP6550083B2 (ja) Ｈｉｖインテグラーゼ阻害薬として有用な置換されたキノリジン誘導体
EP3752144B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3008044B1 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3330272B1 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3303341B1 (en) Fused tricyclic heterocyclic compounds useful for treating hiv infection
EP3801543B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
EP3548031B1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors
KR20210005139A (ko) Hiv 인테그라제 억제제로서 유용한 트리시클릭 헤테로사이클 화합물
WO2017113288A1 (en) Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
EP3573984A1 (en) Substituted quinolizine derivatives useful as hiv integrase inhibitors
EP3941457B1 (en) Inhibitors of histone deacetylase useful for the treatment or prevention of hiv infection
RU2851203C2 (ru) Тетрациклические гетероциклические соединения, полезные в качестве ингибиторов интегразы вич
AU2022223241B2 (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
US20210115044A1 (en) Tricyclic heterocycle compounds useful as hiv integrase inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination